Display options
Cite
Li CH, Yu TB, Qiu HW, et al. miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. Oncol Lett. 2017;13(4):2191-2197doi: 10.3892/ol.2017.5709.
Li, C. H., Yu, T. B., Qiu, H. W., Zhao, X., Zhou, C. L., & Qi, C. (2017). miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. Oncology letters, 13(4), 2191-2197. https://doi.org/10.3892/ol.2017.5709
Li, Chang-Hui, et al. "miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1." Oncology letters vol. 13,4 (2017): 2191-2197. doi: https://doi.org/10.3892/ol.2017.5709
Li CH, Yu TB, Qiu HW, Zhao X, Zhou CL, Qi C. miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. Oncol Lett. 2017 Apr;13(4):2191-2197. doi: 10.3892/ol.2017.5709. Epub 2017 Feb 09. PMID: 28454380; PMCID: PMC5403695.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Apr;13(4):2191-2197. doi: 10.3892/ol.2017.5709. Epub 2017 Feb 09.

miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1.

Oncology letters

Chang-Hui Li, Teng-Bo Yu, Hong-Wei Qiu, Xia Zhao, Chuan-Li Zhou, Chao Qi

Affiliations

  1. Department of Orthopedics, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China.
  2. Department of Orthopedics, People's Hospital of Rizhao, Rizhao, Shandong 276826, P.R. China.

PMID: 28454380 PMCID: PMC5403695 DOI: 10.3892/ol.2017.5709

Abstract

Osteosarcoma (OS) is the most common form of bone malignancy in children and adolescents. A class of molecules known as microRNAs (miRNAs) have been routinely associated in the development and progression of OS. The present study was centered on the less well-known miRNA, miRNA (miR)-150, and its role in OS was investigated. The levels of miR-150 were examined in 40 tissue specimens from patients with OS and adjacent normal tissues using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. In addition the expression levels of miR-150 were examined in three OS cell lines and a normal osteoblast cell line. Cell proliferation, migration and invasion assays were performed to establish the correlation between miR-150 and metastasis. The potential targets of miR-150 were theoretically predicted and one high-scoring target, Rho-associated kinase 1 (ROCK1), was established to be a direct target using RT-qPCR and western blot analyses and Pearson's correlation analysis. The results indicated that miR-150 was downregulated in tissues from patients with OS and cell lines. Secondly, it was shown that the overexpression of miR-150 was inversely correlated with OS cell proliferation, migration and invasion. It was also shown that miR-150 negatively regulated the gene expression of ROCK1 in the OS cell lines. Finally, the interaction between miR-150 and ROCK1 was established and it was shown that miR-150 directly targeted ROCK1. In conclusion, miR-150 was found to be a tumor suppressor, and the suppression of miR-150 resulted in elevation in the levels of ROCK1. This interaction between miR-150 and ROCK1 may be key in the progression of OS. Furthermore, miR-150 or ROCK1 may be potential therapeutic targets for the treatment of OS.

Keywords: Rho-associated protein kinase 1; metastasis; microRNA-150; osteosarcoma; tumor suppressor

References

  1. PLoS One. 2013 May 10;8(5):e61015 - PubMed
  2. Cancer Res. 2012 Apr 1;72(7):1865-77 - PubMed
  3. Am Fam Physician. 2002 Mar 15;65(6):1123-32 - PubMed
  4. Leukemia. 2011 Aug;25(8):1324-34 - PubMed
  5. Biochem Biophys Res Commun. 2013 Aug 9;437(4):653-8 - PubMed
  6. Sarcoma. 2011;2011:732690 - PubMed
  7. Cancer Sci. 2013 Jan;104(1):48-54 - PubMed
  8. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19678-83 - PubMed
  9. Nature. 2005 Jun 9;435(7043):834-8 - PubMed
  10. Clin Cancer Res. 2011 Dec 15;17 (24):7574-83 - PubMed
  11. Br J Cancer. 2011 Jan 18;104(2):308-15 - PubMed
  12. Biochem Biophys Res Commun. 2010 Feb 12;392(3):340-5 - PubMed
  13. EMBO Rep. 2012 Oct;13(10):900-8 - PubMed
  14. Nat Rev Cancer. 2006 Apr;6(4):259-69 - PubMed
  15. Cancer Cell. 2012 Oct 16;22(4):524-35 - PubMed
  16. Cancer Treat Res. 2009;152:3-13 - PubMed
  17. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  18. FEBS Lett. 2013 Aug 2;587(15):2346-51 - PubMed
  19. Paediatr Drugs. 2008;10(5):315-27 - PubMed
  20. Gut. 2012 Oct;61(10):1447-53 - PubMed
  21. Oncol Lett. 2012 Nov;4(5):1037-1042 - PubMed

Publication Types